Baricitinib Noninferior to Etanercept for Reducing Ultrasound-Assessed Synovitis

Managing active rheumatoid arthritis often necessitates a transition to targeted therapies for patients who do not achieve adequate control with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [1, 2]. While clinical response is frequently assessed using composite indices like the American College of Rheumatology (ACR) criteria, these measures can be confounded by subjective patient-reported outcomes, including individual perceptions of pain and fatigue [3, 4]. Although oral Janus kinase (JAK) inhibitors such as baricitinib have shown efficacy in achieving clinical remission and slowing radiographic progression, with ACR20 response rates of 70% at 12 weeks in methotrexate-inadequate responders, clinicians require objective confirmation that these agents suppress active joint inflammation as effectively as established injectable biologics [5, 6, 7, 8, 9]. A recent international multicenter trial of 150 patients provides this evidence, demonstrating that baricitinib is noninferior to etanercept in reducing the Global European Alliance of Associations for Rheumatology-Outcome Measures in Rheumatology Synovitis Score (GLOESS), a standardized ultrasound measure of synovial tissue inflammation (p < 0.050) [10].